[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614228":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":56,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"National Cancer Institute, Egypt","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group DF","EXPERIMENTAL","Patients will receive 2.5 mL of 0.5% hyperbaric bupivacaine with 25 µg fentanyl + 5 µg dexmedetomidine.",[13],"Drug: Fentanyl + Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Group F","ACTIVE_COMPARATOR","Patients will receive 2.5 mL of 0.5% hyperbaric bupivacaine with 25 µg fentanyl.",[19],"Drug: Fentanyl",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Fentanyl + Dexmedetomidine",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Fentanyl",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Mai M Elrawas, MD","CONTACT","00201222177242","mai.elrawas@nci.cu.edu.eg",[36],{"facility":37,"status":38,"city":39,"state":25,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"National Cancer Institute","RECRUITING","Cairo","11796","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.24967,30.06263,{"lat":47,"lon":46},[50,51,54],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Mohamed A Wadod, MD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":53,"phone":25,"phoneExt":25,"email":25},"Doaa A Abdou, MD",{"type":53,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mai Mohamed El Rawas","Assistant professor of Anaesthesia, Intensive Care and Pain Management, National Cancer Institute, Cairo University Cairo University, Cairo, Egypt.","100614228","intrathecal-dexmedetomidine-fentanyl-combination-versus-fentanyl-alone-as-adjuvant-to-bupivacaine-in-spinal-anesthesia-for-above-knee-amputation-in-sarcomas-of-lower-extremity-100614228",false,"NCT07276867","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity: A Randomized, Comparative Study","Inclusion Criteria:\n\n* Age from 18 to 60 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status of II-III.\n* Height between 150-185 cm.\n* Body mass index between 18-35 kg\u002Fm².\n* Scheduled for above-knee amputation due to lower limb sarcomas.\n\nExclusion Criteria:\n\n* Allergy to any of the investigated drugs.\n* History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.\n* Contraindications to spinal anesthesia.\n* Pregnancy or lactation.\n* Presence of psychiatric illness or chronic pain conditions.","ALL","18 Years","60 Years",{"count":70,"type":71},58,"ESTIMATED","INTERVENTIONAL",[74],"NA","The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.",[77,78,27,79,80,81,82,83],"Intrathecal","Dexmedetomidine","Bupivacaine","Spinal Anesthesia","Above Knee Amputation","Sarcomas","Lower Extremity","2025-11-30",{"date":86,"type":87},"2025-12-11","ACTUAL",{"date":89,"type":87},"2025-10-20",{"date":91,"type":71},"2026-04-01",{"name":5,"class":6},1]